This website uses cookies to collect usage information in order to offer a better browsing experience. By browsing this site or by clicking on the "ACCEPT COOKIES" button you accept our Cookie Policy.

Why Uber Is Bringing Medicine to Your Door

Prescription delivery started taking off just before the pandemic. Now big players like Uber are getting involved.

In 2020, Uber realized that its delivery services were far more profitable and popular than its ridesharing services. The pandemic is easing up in the United States, but Uber isn’t going all-in on the return to carpools that some may have thought it might. Instead, it’s strengthening its delivery presence by branching out into other areas, like prescription delivery.

Uber announced this week that it is partnering with prescription startup ScriptDrop to bring prescription delivery services to 37 states. This is the second partnership Uber has launched with a health tech startup, the first being a partnership with NimbleRx last August in the midst of the pandemic.

Prescription delivery services were attracting significant investor attention even before the pandemic, but the high demand caused by the pandemic thrust the market into the mainstream. ScriptDrop itself is a great example of the rapid rise of prescription delivery. In 2019, it raised a seed round totalling $250,000. In February last year, it announced another venture round raising $2 million. When it came time for its Series A in October, it raised $15 million.

Capsule, PillPack, NimbleRx - LinkedIn Headcount

Uber’s partnership with NimbleRX has proved beneficial for the startup, which has doubled its headcount since this time last year.

Though Uber has partnered with two different prescription startups to launch its delivery service, there are other major competitors in the space. PillPack, acquired by Amazon in 2018 for $753 million, has increased its headcount by 23% year-over-year. Rumors of Amazon-owned pharmacies opening have swirled since the acquisition, but the scale required to compete with existing brick-and-mortar pharmacies makes delivery the more appealing option.

Capsule remains another major competitor in the space, having raised a total of $570 million — with $300 million coming from its Series D in April — though it serves far fewer locations than Uber’s delivery service will. Last year, Capsule had just begun expanding into the Twin Cities, Boston, and Chicago, but it has since added Los Angeles and Austin to the list of cities it serves. The company’s headcount has increased by 51% since last year.

About the Data:

Thinknum tracks companies using the information they post online, jobs, social and web traffic, product sales, and app ratings, and creates data sets that measure factors like hiring, revenue, and foot traffic. Data sets may not be fully comprehensive (they only account for what is available on the web), but they can be used to gauge performance factors like staffing and sales.

Originally Posted on June 16, 2021 – Why Uber Is Bringing Medicine to Your Door

Disclosure: Interactive Brokers

Information posted on IBKR Traders’ Insight that is provided by third-parties and not by Interactive Brokers does NOT constitute a recommendation by Interactive Brokers that you should contract for the services of that third party. Third-party participants who contribute to IBKR Traders’ Insight are independent of Interactive Brokers and Interactive Brokers does not make any representations or warranties concerning the services offered, their past or future performance, or the accuracy of the information provided by the third party. Past performance is no guarantee of future results.

This material is from The Business of Business - Thinknum Media and is being posted with permission from The Business of Business - Thinknum Media. The views expressed in this material are solely those of the author and/or The Business of Business - Thinknum Media and IBKR is not endorsing or recommending any investment or trading discussed in the material. This material is not and should not be construed as an offer to sell or the solicitation of an offer to buy any security. To the extent that this material discusses general market activity, industry or sector trends or other broad based economic or political conditions, it should not be construed as research or investment advice. To the extent that it includes references to specific securities, commodities, currencies, or other instruments, those references do not constitute a recommendation to buy, sell or hold such security. This material does not and is not intended to take into account the particular financial conditions, investment objectives or requirements of individual customers. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.

In accordance with EU regulation: The statements in this document shall not be considered as an objective or independent explanation of the matters. Please note that this document (a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and (b) is not subject to any prohibition on dealing ahead of the dissemination or publication of investment research.

Any trading symbols displayed are for illustrative purposes only and are not intended to portray recommendations.

trading top